Literature DB >> 3297254

Reversible serotoninergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse striatum studied by neurochemical and immunohistochemical approaches.

K Hara, I Tohyama, H Kimura, H Fukuda, S Nakamura, M Kameyama.   

Abstract

Effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on serotonin (5-HT) were studied in mouse striatum. The 5-HT level was significantly reduced at 1 week after MPTP, though returned at 4 weeks. The level of 5-hydroxyindoleacetic acid (5-HIAA) increased at both 1 and 4 weeks. The ratio of increase in 5-HT induced by pargyline administration was larger in MPTP-pretreated mice than in vehicle-pretreated controls at 1 week, although it was identical in both groups at 4 weeks. The 5-HT immunohistochemical study confirmed the biochemical change of 5-HT. These results suggest that MPTP functionally affects the 5-HT metabolism in mouse striatum.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3297254     DOI: 10.1016/0006-8993(87)90341-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

1.  Monoamine changes in the brain of BALB/c mice following sub-lethal infection with Nocardia asteroides (GUH-2).

Authors:  K Hyland; B L Beaman; P A LeWitt; A J DeMaggio
Journal:  Neurochem Res       Date:  2000-04       Impact factor: 3.996

2.  5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease.

Authors:  Marcus C Ferguson; Tultul Nayyar; Ariel Y Deutch; Twum A Ansah
Journal:  Neuropharmacology       Date:  2010-03-31       Impact factor: 5.250

Review 3.  Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Mol Neurobiol       Date:  2012-01-06       Impact factor: 5.590

4.  Further confirmation of serotonin reduction in the neostriatum during hyperthermia-induced convulsions: a quantitative immunohistochemical study.

Authors:  Y Takeuchi; K Fujiwara; N Sato; M Tominaga; K Hasegawa; T Osamura; T Sawada
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

5.  Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervation.

Authors:  Tultul Nayyar; Michael Bubser; Marcus C Ferguson; M Diana Neely; J Shawn Goodwin; Thomas J Montine; Ariel Y Deutch; Twum A Ansah
Journal:  Eur J Neurosci       Date:  2009-07       Impact factor: 3.386

Review 6.  Advances in non-dopaminergic treatments for Parkinson's disease.

Authors:  Sandy Stayte; Bryce Vissel
Journal:  Front Neurosci       Date:  2014-05-22       Impact factor: 4.677

7.  Chronic Systemic Inflammation Exacerbates Neurotoxicity in a Parkinson's Disease Model.

Authors:  Perla Ugalde-Muñiz; Ingrid Fetter-Pruneda; Luz Navarro; Esperanza García; Anahí Chavarría
Journal:  Oxid Med Cell Longev       Date:  2020-01-13       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.